

## List of Publications

1. Baumann, H., Knapp, S., Lundback, T., Ladenstein, R., and Hard, T. (1994). Solution structure and DNA-binding properties of a thermostable protein from the archaeon *Sulfolobus solfataricus*. **Nat Struct Biol** 1, 808-819.
2. Klug, J., Knapp, S., Castro, I., and Beato, M. (1994). Two distinct factors bind to the rabbit uteroglobin TATA-box region and are required for efficient transcription. **Mol Cell Biol** 14, 6208-6218.
3. Knapp, S., Schmidt-Krey, I., Hebert, H., Bergman, T., Jornvall, H., and Ladenstein, R. (1994). The molecular chaperonin TF55 from the Thermophilic archaeon *Sulfolobus solfataricus*. A biochemical and structural characterization. **J Mol Biol** 242, 397-407.
4. Baumann, H., Knapp, S., Karshikoff, A., Ladenstein, R., and Hard, T. (1995). DNA-binding surface of the Sso7d protein from *Sulfolobus solfataricus*. **J Mol Biol** 247, 840-846.
5. Berglund, H., Baumann, H., Knapp, S., Ladenstein, R., and Haerd, T. (1995). Flexibility of an Arginine Side Chain at a DNA-Protein Interface. *Journal of the American Chemical Society* 117, 12883-12884.
6. Knapp, S., Karshikoff, A., Waldkotter, K., Rudiger, A., Antranikian, G., and Ladenstein, R. (1995). Preliminary crystallographic analysis of an extremely thermostable glutamate dehydrogenase from the archaeon *Pyrococcus woesei*. *Acta Crystallogr D Biol Crystallogr* 51, 395-398.
7. Knapp, S., Rudiger, A., Antranikian, G., Jorgensen, P.L., and Ladenstein, R. (1995). Crystallization and preliminary crystallographic analysis of an amylopullulanase from the hyperthermophilic archaeon *Pyrococcus woesei*. *Proteins* 23, 595-597. Benach, J., Knapp, S., Oppermann, U.C., Hagglund, O., Jornvall, H., and Ladenstein, R. (1996). Crystallization and crystal packing of recombinant 3 (or 17) beta-hydroxysteroid dehydrogenase from *Comamonas testosteroni* ATTC 11996. **Eur J Biochem** 236, 144-148.
8. Knapp, S. (1996). On the stability of proteins from hyperthermophiles: A structural and thermodynamic study. **Thesis Karolinska Institute Stockholm**.
9. Benach, J., Knapp, S., Oppermann, U.C., Hagglund, O., Jornvall, H., and Ladenstein, R. (1996). Crystallization and crystal packing of recombinant 3 (or 17) beta-hydroxysteroid dehydrogenase from *Comamonas testosteroni* ATTC 11996. **Eur J Biochem** 236, 144-148.
10. Knapp, S., Karshikoff, A., Berndt, K.D., Christova, P., Atanasov, B., and Ladenstein, R. (1996). Thermal unfolding of the DNA-binding protein Sso7d from the hyperthermophile *Sulfolobus solfataricus*. **J Mol Biol** 264, 1132-1144.
11. Knapp, S., de Vos, W.M., Rice, D., and Ladenstein, R. (1997). Crystal structure of glutamate dehydrogenase from the hyperthermophilic eubacterium *Thermotoga maritima* at 3.0 Å resolution. **J Mol Biol** 267, 916-932.
12. Agback, P., Baumann, H., Knapp, S., Ladenstein, R., and Hard, T. (1998). Architecture of nonspecific protein-DNA interactions in the Sso7d-DNA complex. **Nature Structural Biology** 5, 579-584.
13. Ellis, M.J., Knapp, S., Koeck, P.J., Fakoor-Biniazi, Z., Ladenstein, R., and Hebert, H. (1998). Two-dimensional crystallization of the chaperonin TF55 from the hyperthermophilic archaeon *Sulfolobus solfataricus*. **J Struct Biol** 123, 30-36.
14. Knapp, S. (1998). Development of bacterial expression systems for topoisomerases from extremophilic organisms. **BIF Futura** 13, 55-57.
15. Knapp, S., Mattson, P.T., Christova, P., Berndt, K.D., Karshikoff, A., Vihinen, M., Smith, C.I., and Ladenstein, R. (1998). Thermal unfolding of small proteins with SH3 domain folding pattern. **Proteins** 31, 309-319.

16. Lopez-Garcia, P., Knapp, S., Ladenstein, R., and Forterre, P. (1998). In vitro DNA binding of the archaeal protein Sso7d induces negative supercoiling at temperatures typical for thermophilic growth. **Nucleic Acids Res** 26, 2322-2328.
17. Lundback, T., Hansson, H., Knapp, S., Ladenstein, R., and Hard, T. (1998). Thermodynamic characterization of non-sequence-specific DNA-binding by the Sso7d protein from *Sulfolobus solfataricus*. **J Mol Biol** 276, 775-786.
18. Oppermann, U.C., Knapp, S., Bonetto, V., Ladenstein, R., and Jornvall, H. (1998). Isolation and structure of repressor-like proteins from the archaeon *Sulfolobus solfataricus*. Co-purification of RNase A with Sso7c. **FEBS Lett** 432, 141-144.
19. Forterre, P., Confalonieri, F., and Knapp, S. (1999). Identification of the gene encoding archeal-specific DNA-binding proteins of the Sac10b family. **Molecular Microbiology** 32, 669-670.
20. Knapp, S., Kardinahl, S., Hellgren, N., Tibbelin, G., Schafer, G., and Ladenstein, R. (1999). Refined crystal structure of a superoxide dismutase from the hyperthermophilic archaeon *Sulfolobus acidocaldarius* at 2.2 Å resolution. **J Mol Biol** 285, 689-702.
21. Knapp, S., Ladenstein, R., and Galinski, E.A. (1999). Extrinsic protein stabilization by the naturally occurring osmolytes beta-hydroxyectoine and betaine. **Extremophiles** 3, 191-198.
22. Lebbink, J.H.G., Knapp, S., van der Oost, J., Rice, D., Ladenstein, R., and de Vos, W.M. (1999). Engineering activity and stability of *Thermotoga maritima* glutamate dehydrogenase. II: construction of a 16-residue ion-pair network at the subunit interface. **J Mol Biol** 289, 357-369.
23. Vecsey-Semjen, B., Knapp, S., Mollby, R., and van der Goot, F.G. (1999). The staphylococcal alpha-toxin pore has a flexible conformation. **Biochemistry** 38, 4296-4302.
24. Consalvi, V., Chiaraluce, R., Giangiacomo, L., Scandurra, R., Christova, P., Karshikoff, A., Knapp, S., and Ladenstein, R. (2000). Thermal unfolding and conformational stability of the recombinant domain II of glutamate dehydrogenase from the hyperthermophile *Thermotoga maritima*. **Protein Eng** 13, 501-507.
25. Knapp, S., Zamai, M., Volpi, D., Nardese, V., Avanzi, N., Breton, J., Plyte, S., Flocco, M., Marconi, M., Isacchi, A., and Caiolfa, V.R. (2001). Thermodynamics of the high-affinity interaction of TCF4 with beta-catenin. **J Mol Biol** 306, 1179-1189.
26. Muller, S., Bianchi, M.E., and Knapp, S. (2001). Thermodynamics of HMGB1 interaction with duplex DNA. **Biochemistry** 40, 10254-10261.
27. Dalvit, C., Fasolini, M., Flocco, M., Knapp, S., Pevarello, P., and Veronesi, M. (2002). NMR-Based screening with competition water-ligand observed via gradient spectroscopy experiments: detection of high-affinity ligands. **J Med Chem** 45, 2610-2614.
28. Dalvit, C., Flocco, M., Knapp, S., Mostardini, M., Perego, R., Stockman, B.J., Veronesi, M., and Varasi, M. (2002). High-throughput NMR-based screening with competition binding experiments. **J Am Chem Soc** 124, 7702-7709.
29. Filling, C., Berndt, K.D., Benach, J., Knapp, S., Prozorovski, T., Nordling, E., Ladenstein, R., Jornvall, H., and Oppermann, U. (2002). Critical residues for structure and catalysis in short-chain dehydrogenases/reductases. **J Biol Chem** 277, 25677-25684.
30. Sironi, L., Mapelli, M., Knapp, S., De Antoni, A., Jeang, K.T., and Musacchio, A. (2002). Crystal structure of the tetrameric Mad1-Mad2 core complex: implications of a 'safety belt' binding mechanism for the spindle checkpoint. **EMBO J** 21, 2496-2506.

31. Bertrand, J.A., Thieffine, S., Vulpetti, A., Cristiani, C., Valsasina, B., Knapp, S., Kalisz, H.M., and Flocco, M. (2003). Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. **J Mol Biol** 333, 393-407.
32. Faria, T.Q., Knapp, S., Ladenstein, R., Macanita, A.L., and Santos, H. (2003). Protein stabilisation by compatible solutes: effect of mannosylglycerate on unfolding thermodynamics and activity of ribonuclease A. **ChemBiochem** 4, 734-741.
33. Fasolini, M., Wu, X., Flocco, M., Trosset, J.Y., Oppermann, U., and Knapp, S. (2003). Hot spots in Tcf4 for the interaction with beta-catenin. **J Biol Chem** 278, 21092-21098.
34. Lolli, G., Thaler, F., Valsasina, B., Roletto, F., Knapp, S., Uggeri, M., Bachi, A., Matafora, V., Storici, P., Stewart, A., Kalisz, H.M., and Isacchi, A. (2003). Inhibitor affinity chromatography: profiling the specific reactivity of the proteome with immobilized molecules. **Proteomics** 3, 1287-1298.
35. Schiering, N., Knapp, S., Marconi, M., Flocco, M.M., Cui, J., Perego, R., Rusconi, L., and Cristiani, C. (2003). Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. **Proc Natl Acad Sci U S A** 100, 12654-12659.
36. Knapp, S., Muller, S., Digilio, G., Bonaldi, T., Bianchi, M.E., and Musco, G. (2004). The long acidic tail of high mobility group box 1 (HMGB1) protein forms an extended and flexible structure that interacts with specific residues within and between the HMG boxes. **Biochemistry** 43, 11992-11997.
37. Tarricone, C., Perrina, F., Monzani, S., Massimiliano, L., Kim, M.H., Derewenda, Z.S., Knapp, S., Tsai, L.H., and Musacchio, A. (2004). Coupling PAF signaling to dynein regulation: structure of LIS1 in complex with PAF-acetylhydrolase. **Neuron** 44, 809-821.
38. Bullock, A.N., Debreczeni, J., Amos, A.L., Knapp, S., and Turk, B.E. (2005). Structure and substrate specificity of the Pim-1 kinase. **J Biol Chem** 280, 41675-41682.
39. Bullock, A.N., Debreczeni, J.E., Fedorov, O.Y., Nelson, A., Marsden, B.D., and Knapp, S. (2005). Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. **J Med Chem** 48, 7604-7614.
40. Cristiani, C., Rusconi, L., Perego, R., Schiering, N., Kalisz, H.M., Knapp, S., and Isacchi, A. (2005). Regulation of the wild-type and Y1235D mutant Met kinase activation. **Biochemistry** 44, 14110-14119.
41. Barr, A.J., Debreczeni, J.E., Eswaran, J., and Knapp, S. (2006). Crystal structure of human protein tyrosine phosphatase 14 (PTPN14) at 1.65-A resolution. **Proteins** 63, 1132-1136.
42. Barr, A.J., and Knapp, S. (2006). MAPK-specific tyrosine phosphatases: new targets for drug discovery? **Trends Pharmacol Sci** 27, 525-530.
43. Bullock, A.N., Debreczeni, J.E., Edwards, A.M., Sundstrom, M., and Knapp, S. (2006). Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. **Proc Natl Acad Sci U S A** 103, 7637-7642.
44. Debreczeni, J.E., Bullock, A.N., Atilla, G.E., Williams, D.S., Bregman, H., Knapp, S., and Meggers, E. (2006). Ruthenium half-sandwich complexes bound to protein kinase Pim-1. **Angew Chem Int Ed Engl** 45, 1580-1585.
45. Eswaran, J., Debreczeni, J.E., Longman, E., Barr, A.J., and Knapp, S. (2006). The crystal structure of human receptor protein tyrosine phosphatase kappa phosphatase domain 1. **Protein Sci** 15, 1500-1505.
46. Eswaran, J., von Kries, J.P., Marsden, B., Longman, E., Debreczeni, J.E., Ugochukwu, E., Turnbull, A., Lee, W.H., Knapp, S., and Barr, A.J. (2006). Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases. **Biochem J** 395, 483-491.

47. Kavanagh, K.L., Guo, K., Dunford, J.E., Wu, X., Knapp, S., Ebetino, F.H., Rogers, M.J., Russell, R.G., and Oppermann, U. (2006). The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. **Proc Natl Acad Sci U S A** *103*, 7829-7834.
48. Marsden, B., Sundstrom, M., and Knapp, S. (2006). High Throughput Structural Characterization of Therapeutic Protein Targets. *Expert Opinion in Drug Discovery* *1*, 123-136.
49. Trosset, J.Y., Dalvit, C., Knapp, S., Fasolini, M., Veronesi, M., Mantegani, S., Gianellini, L.M., Catana, C., Sundstrom, M., Stouten, P.F., and Moll, J.K. (2006). Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. **Proteins** *64*, 60-67.
50. Baminger, B., Ludwiczek, M.L., Kontaxis, G., Knapp, S., and Konrat, R. (2007). Protein-protein interaction site mapping using NMR-detected mutational scanning. **J Biomol NMR** *38*, 133-137.
51. Bullock, A.N., Rodriguez, M.C., Debreczeni, J.E., Songyang, Z., and Knapp, S. (2007). Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. **Structure** *15*, 1493-1504.
52. Bunkoczi, G., Salah, E., Filippakopoulos, P., Fedorov, O., Muller, S., Sobott, F., Parker, S.A., Zhang, H., Min, W., Turk, B.E., and Knapp, S. (2007). Structural and functional characterization of the human protein kinase ASK1. **Structure** *15*, 1215-1226.
53. Eswaran, J., Lee, W.H., Debreczeni, J.E., Filippakopoulos, P., Turnbull, A., Fedorov, O., Deacon, S.W., Peterson, J.R., and Knapp, S. (2007). Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. **Structure** *15*, 201-213.
54. Fedorov, O., Marsden, B., Pogacic, V., Rellos, P., Muller, S., Bullock, A.N., Schwaller, J., Sundstrom, M., and Knapp, S. (2007). A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. **Proc Natl Acad Sci U S A** *104*, 20523-20528.
55. Fedorov, O., Sundstrom, M., Marsden, B., and Knapp, S. (2007). Insights for the development of specific kinase inhibitors by targeted structural genomics. **Drug Discov Today** *12*, 365-372.
56. Gileadi, O., Knapp, S., Lee, W.H., Marsden, B.D., Muller, S., Niesen, F.H., Kavanagh, K.L., Ball, L.J., von Delft, F., Doyle, D.A., Oppermann, U.C., and Sundstrom, M. (2007). The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins. **J Struct Funct Genomics** *8*, 107-119.
57. Oliver, A.W., Knapp, S., and Pearl, L.H. (2007). Activation segment exchange: a common mechanism of kinase autophosphorylation? **Trends in Biochemical Sciences** *32*, 351-356.
58. Pogacic, V., Bullock, A.N., Fedorov, O., Filippakopoulos, P., Gasser, C., Biondi, A., Meyer-Monard, S., Knapp, S., and Schwaller, J. (2007). Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. **Cancer Res** *67*, 6916-6924.
59. Rellos, P., Ivins, F.J., Baxter, J.E., Pike, A., Nott, T.J., Parkinson, D.M., Das, S., Howell, S., Fedorov, O., Shen, Q.Y., Fry, A.M., Knapp, S., and Smerdon, S.J. (2007). Structure and regulation of the human Nek2 centrosomal kinase. **J Biol Chem** *282*, 6833-6842.
60. Rennefahrt, U.E., Deacon, S.W., Parker, S.A., Devarajan, K., Beeser, A., Chernoff, J., Knapp, S., Turk, B.E., and Peterson, J.R. (2007). Specificity profiling of Pak kinases allows identification of novel phosphorylation sites. **J Biol Chem** *282*, 15667-15678.
61. Rosettani, P., Knapp, S., Vismara, M.G., Rusconi, L., and Cameron, A.D. (2007). Structures of the human eIF4E homologous protein, h4EHP, in its m7GTP-bound and unliganded forms. **J Mol Biol** *368*, 691-705.

62. Wu, X., Knapp, S., Stamp, A., Stammers, D.K., Jornvall, H., Dellaporta, S.L., and Oppermann, U. (2007). Biochemical characterization of TASSELSEED 2, an essential plant short-chain dehydrogenase/reductase with broad spectrum activities. **FEBS J** 274, 1172-1182.
63. Atilla-Gokcumen, G.E., Pagano, N., Streu, C., Maksimoska, J., Filippakopoulos, P., Knapp, S., and Meggers, E. (2008). Extremely tight binding of a ruthenium complex to glycogen synthase kinase 3. **ChemBiochem** 9, 2933-2936.
64. Baumli, S., Lolli, G., Lowe, E.D., Troiani, S., Rusconi, L., Bullock, A.N., Debreczeni, J.E., Knapp, S., and Johnson, L.N. (2008). The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. **EMBO J** 27, 1907-1918.
65. Eswaran, J., Bernad, A., Ligos, J.M., Guinea, B., Debreczeni, J.E., Sobott, F., Parker, S.A., Najmanovich, R., Turk, B.E., and Knapp, S. (2008). Structure of the human protein kinase MPSK1 reveals an atypical activation loop architecture. **Structure** 16, 115-124.
66. Eswaran, J., Soundararajan, M., Kumar, R., and Knapp, S. (2008). UnPAKING the class differences among p21-activated kinases. **Trends Biochem Sci** 33, 394-403.
67. Filippakopoulos, P., Kofler, M., Hantschel, O., Gish, G.D., Grebien, F., Salah, E., Neudecker, P., Kay, L.E., Turk, B.E., Superti-Furga, G., Pawson, T., and Knapp, S. (2008). Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. **Cell** 134, 793-803.
68. Graslund, S., Nordlund, P., Weigelt, J., Hallberg, B.M., Bray, J., Gileadi, O., Knapp, S., Oppermann, U., Arrowsmith, C., Hui, R., Ming, J., dhe-Paganon, S., Park, H.W., Savchenko, A., Yee, A., Edwards, A., Vincentelli, R., Cambillau, C., Kim, R., Kim, S.H., Rao, Z., Shi, Y., Terwilliger, T.C., Kim, C.Y., Hung, L.W., Waldo, G.S., Peleg, Y., Albeck, S., Unger, T., Dym, O., Prilusky, J., Sussman, J.L., Stevens, R.C., Lesley, S.A., Wilson, I.A., Joachimiak, A., Collart, F., Dementieva, I., Donnelly, M.I., Eschenfeldt, W.H., Kim, Y., Stols, L., Wu, R., Zhou, M., Burley, S.K., Emtage, J.S., Sauder, J.M., Thompson, D., Bain, K., Luz, J., Gheyi, T., Zhang, F., Atwell, S., Almo, S.C., Bonanno, J.B., Fiser, A., Swaminathan, S., Studier, F.W., Chance, M.R., Sali, A., Acton, T.B., Xiao, R., Zhao, L., Ma, L.C., Hunt, J.F., Tong, L., Cunningham, K., Inouye, M., Anderson, S., Janjua, H., Shastry, R., Ho, C.K., Wang, D., Wang, H., Jiang, M., Montelione, G.T., Stuart, D.I., Owens, R.J., Daenke, S., Schutz, A., Heinemann, U., Yokoyama, S., Bussow, K., and Gunsalus, K.C. (2008). Protein production and purification. **Nat Methods** 5, 135-146.
69. Maksimoska, J., Williams, D.S., Atilla-Gokcumen, G.E., Smalley, K.S., Carroll, P.J., Webster, R.D., Filippakopoulos, P., Knapp, S., Herlyn, M., and Meggers, E. (2008). Similar biological activities of two isostructural ruthenium and osmium complexes. **Chemistry** 14, 4816-4822.
70. Marsden, B.D., and Knapp, S. (2008). Doing more than just the structure-structural genomics in kinase drug discovery. **Curr Opin Chem Biol** 12, 40-45.
71. Miller, M.L., Jensen, L.J., Diella, F., Jorgensen, C., Tinti, M., Li, L., Hsiung, M., Parker, S.A., Bordeaux, J., Sicheritz-Ponten, T., Olhovsky, M., Pasculescu, A., Alexander, J., Knapp, S., Blom, N., Bork, P., Li, S., Cesareni, G., Pawson, T., Turk, B.E., Yaffe, M.B., Brunak, S., and Linding, R. (2008). Linear motif atlas for phosphorylation-dependent signaling. **Sci Signal** 1, ra2.
72. Pike, A.C., Rellos, P., Niesen, F.H., Turnbull, A., Oliver, A.W., Parker, S.A., Turk, B.E., Pearl, L.H., and Knapp, S. (2008). Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites. **EMBO J** 27, 704-714.
73. Wu, X., Oppermann, M., Berndt, K.D., Bergman, T., Jornvall, H., Knapp, S., and Oppermann, U. (2008). Thermal unfolding of the archaeal DNA and RNA binding protein Ssh10. **Biochem Biophys Res Commun** 373, 482-487.

74. Akue-Gedu, R., Rossignol, E., Azzaro, S., Knapp, S., Filippakopoulos, P., Bullock, A.N., Bain, J., Cohen, P., Prudhomme, M., Anizon, F., and Moreau, P. (2009). Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. **J Med Chem** 52, 6369-6381.
75. Barr, A.J., and Knapp, S. (2009). Scale Structural Analysis of Protein Tyrosine Phosphatases. **Handbook in Cell Signalling** 2nd Edition Eds Bradshaw & Dennis.
76. Barr, A.J., Ugochukwu, E., Lee, W.H., King, O.N., Filippakopoulos, P., Alfano, I., Savitsky, P., Burgess-Brown, N.A., Muller, S., and Knapp, S. (2009). Large-scale structural analysis of the classical human protein tyrosine phosphatome. **Cell** 136, 352-363.
77. Bullock, A.N., Das, S., Debreczeni, J.E., Rellos, P., Fedorov, O., Niesen, F.H., Guo, K., Papagrigoriou, E., Amos, A.L., Cho, S., Turk, B.E., Ghosh, G., and Knapp, S. (2009). Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. **Structure** 17, 352-362.
78. Bullock, A.N., Russo, S., Amos, A., Pagano, N., Bregman, H., Debreczeni, J.E., Lee, W.H., von Delft, F., Meggers, E., and Knapp, S. (2009). Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor. **PLoS One** 4, e7112.
79. Coutandin, D., Lohr, F., Niesen, F.H., Ikeya, T., Weber, T.A., Schafer, B., Zielonka, E.M., Bullock, A.N., Yang, A., Guntert, P., Knapp, S., McKeon, F., Ou, H.D., and Dotsch, V. (2009). Conformational stability and activity of p73 require a second helix in the tetramerization domain. **Cell Death Differ** 16, 1582-1589.
80. Elkins, J.M., Amos, A., Niesen, F.H., Pike, A.C., Fedorov, O., and Knapp, S. (2009). Structure of dystrophia myotonica protein kinase. **Protein Sci** 18, 782-791.
81. Eswaran, J., Patnaik, D., Filippakopoulos, P., Wang, F., Stein, R.L., Murray, J.W., Higgins, J.M., and Knapp, S. (2009). Structure and functional characterization of the atypical human kinase haspin. **Proc Natl Acad Sci U S A** 106, 20198-20203.
82. Eswaran, J., Soundararajan, M., and Knapp, S. (2009). Targeting group II PAKs in cancer and metastasis. **Cancer Metastasis Rev** 28, 209-217.
83. Filippakopoulos, P., Muller, S., and Knapp, S. (2009). SH2 domains: modulators of nonreceptor tyrosine kinase activity. **Curr Opin Struct Biol** 19, 643-649.
84. Gingras, M.C., Zhang, Y.L., Kharitidi, D., Barr, A.J., Knapp, S., Tremblay, M.L., and Pause, A. (2009). HD-PTP is a catalytically inactive tyrosine phosphatase due to a conserved divergence in its phosphatase domain. **PLoS One** 4, e5105.
85. Grundler, R., Brault, L., Gasser, C., Bullock, A.N., Dechow, T., Woetzel, S., Pogacic, V., Villa, A., Ehret, S., Berridge, G., Spoo, A., Dierks, C., Biondi, A., Knapp, S., Duyster, J., and Schwaller, J. (2009). Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. **J Exp Med** 206, 1957-1970.
86. Huber, K., Feyen, O., Ruschendorf, F., Knapp, S., and Borkhardt, A. (2009). Identification of a novel primary immunodeficiency syndrome leading to an XLP-like phenotype in girls. **EUR J PEDIATR** 168, 380.
87. Huck, K., Feyen, O., Niehues, T., Ruschendorf, F., Hubner, N., Laws, H.J., Telieps, T., Knapp, S., Wacker, H.H., Meindl, A., Jumaa, H., and Borkhardt, A. (2009). Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. **J Clin Invest** 119, 1350-1358.
88. Kimple, A.J., Soundararajan, M., Hutsell, S.Q., Roos, A.K., Urban, D.J., Setola, V., Temple, B.R., Roth, B.L., Knapp, S., Willard, F.S., and Siderovski, D.P. (2009). Structural determinants of G-protein alpha subunit selectivity by regulator of G-protein signaling 2 (RGS2). **J Biol Chem** 284, 19402-19411.

89. Muller, S., and Knapp, S. (2009). Out of the box binding determines specificity of SH2 domain interaction. **Structure** 17, 1040-1041.
90. Scheeff, E.D., Eswaran, J., Bunkoczi, G., Knapp, S., and Manning, G. (2009). Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. **Structure** 17, 128-138.
91. Telieps, T., Huck, K., Feyen, O., Niehues, T., Ruschendorf, F., Hubner, N., Laws, H.J., Knapp, S., Wacker, H.H., Meindl, A., Jumaa, H., and Borkhardt, A. (2009). Missense mutation in the inducible T-cell kinase (ITK) leading to immunodeficiency and fatal immune dysregulation after EBV infection. **Klin Pediat** 221, 209-209.
92. Ugele, M., Sasse, F., Knapp, S., Fedorov, O., Zubriene, A., Matulis, D., and Maier, M.E. (2009). Propionate analogues of zearalenone bind to Hsp90. **Chembiochem** 10, 2203-2212.
93. Zimmermann, T.J., Niesen, F.H., Pilka, E.S., Knapp, S., Oppermann, U., and Maier, M.E. (2009). Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone. **Bioorg Med Chem** 17, 530-536.
94. Brault, L., Gasser, C., Bracher, F., Huber, K., Knapp, S., and Schwaller, J. (2010). PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. **Haematologica** 95, 1004-1015.
95. Eswaran, J., and Knapp, S. (2010). Insights into protein kinase regulation and inhibition by large scale structural comparison. **Biochim Biophys Acta** 1804, 429-432.
96. Fedorov, O., Muller, S., and Knapp, S. (2010). The (un)targeted cancer kinome. **Nat Chem Biol** 6, 166-169.
97. Record, C.J., Chaikuad, A., Rellos, P., Das, S., Pike, A.C., Fedorov, O., Marsden, B.D., Knapp, S., and Lee, W.H. (2010). Structural comparison of human mammalian ste20-like kinases. **PLoS One** 5, e11905.
98. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W.B., Fedorov, O., Morse, E.M., Keates, T., Hickman, T.T., Felleter, I., Philpott, M., Munro, S., McKeown, M.R., Wang, Y., Christie, A.L., West, N., Cameron, M.J., Schwartz, B., Heightman, T.D., La Thangue, N., French, C.A., Wiest, O., Kung, A.L., Knapp, S\*, and Bradner, J.E.\* (2010). Selective inhibition of BET bromodomains. **Nature** 468, 1067-1073. (\*shared correspondence)
99. Kwiatkowski, N., Jelluma, N., Filippakopoulos, P., Soundararajan, M., Manak, M.S., Kwon, M., Choi, H.G., Sim, T., Deveraux, Q.L., Rottmann, S., Pellman, D., Shah, J.V., Kops, G.J., Knapp, S., and Gray, N.S. (2010). Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. **Nat Chem Biol** 6, 359-368.
100. Lopez-Ramos, M., Prudent, R., Moucadel, V., Sautel, C.F., Barette, C., Lafanechere, L., Mouawad, L., Grierson, D., Schmidt, F., Florent, J.C., Filippakopoulos, P., Bullock, A.N., Knapp, S., Reiser, J.B., and Cochet, C. (2010). New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights. **FASEB J** 24, 3171-3185.
101. Muller, S., and Knapp, S. (2010). Targeting kinases for the treatment of inflammatory disease. **Expert Opinion in Drug Discovery** 5, 867-881.
102. Rellos, P., Pike, A.C., Niesen, F.H., Salah, E., Lee, W.H., von Delft, F., and Knapp, S. (2010). Structure of the CaMKII $\delta$ /calmodulin complex reveals the molecular mechanism of CaMKII kinase activation. **PLoS Biol** 8, e1000426.
103. Wang, M., Mok, M.W., Harper, H., Lee, W.H., Min, J., Knapp, S., Oppermann, U., Marsden, B., and Schapira, M. (2010). Structural genomics of histone tail recognition. **Bioinformatics** 26, 2629-2630.

104. Fedorov, O., Huber, K., Eisenreich, A., Filippakopoulos, P., King, O., Bullock, A.N., Szklarczyk, D., Jensen, L.J., Fabbro, D., Trappe, J., Rauch, U., Bracher, F., and Knapp, S. (2011). Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing. **Chem Biol** 18, 67-76.
105. Feng, L., Geisselbrecht, Y., Blanck, S., Wilbuer, A., Atilla-Gokcumen, G.E., Filippakopoulos, P., Kraling, K., Celik, M.A., Harms, K., Maksimoska, J., Marmorstein, R., Frenking, G., Knapp, S., Essen, L.-O., and Meggers, E. (2011). Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors. **J Am Chem Soc** 133, 5976-5986.
106. Zadjali, F., Pike, A.C., Vesterlund, M., Sun, J., Wu, C., Li, S.S., Ronnstrand, L., Knapp, S., Bullock, A.N., and Flores-Morales, A. (2011). Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase. **J Biol Chem** 286, 480-490.
107. Deutsch, G.B., Zielonka, E.M., Coutandin, D., Weber, T.A., Schäfer, B., Hannewald, J., Luh, L.M., Durst, F.G., Ibrahim, M., Hoffmann, J., Niesen, F.H., Sentürk, A., Kunkel, H., Brutschy, B., Schleiff, E., Knapp, S., Acker-Palmer, A., Grez, M., McKeon, F., Dötsch, V. (2011). DNA damage in oocytes induces an irreversible switch of the quality control factor TAp63 delta from dimer to tetramer. **Cell** 144(4):566-76.
108. Salah, E., Ugochukwu, E., Barr, A.J., von Delft, F., Knapp, S., and Elkins, J.M. (2011). Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. **J Med Chem** 54, 2359-2367.
109. Miduturu, C.V, Deng, X., Kwiatkowski, N., Yang, W., Filippakopoulos, P., Yang, Q., Chung, E., Knapp, S., Braut, L., Schwaller, J., King, R., Lee, J.-D., Herrgard, S., Zarrinkar, P., Gray, N.S. (2011). High-Throughput Kinase Profiling: A More Efficient Approach towards the Discovery of New Kinase Inhibitors, **Chemistry and Biology**, 18(7), 868-879.
110. Prudent, R., Vassal, E., Nguyen, C.-H., Pillet, C., Barette, C., Soleilhac, E., Martinez, A., Filhol, O., Beghin, A., Aci-Sèche, S., Grierson, D., Antonipillai, J., Li, R., Florent, J.-C., Knapp, S., Bernard, O., Lafanechère L. (2011). A new cell-permeable and reversible inhibitor of LIM Kinase identified in a phenotype-based screen probing for microtubule stability. **Chemistry and Biology**, in press.
111. Debdab, M., Carreaux, F., Renault, S., Soundararajan, M., Fedorov, O., Filippakopoulos, P., Lozach, O., Babault, L., Tahtouh, T., Baratte, B., Ogawa Y, Hagiwara M, Eisenreich A, Rauch U, Knapp S, Meijer L, Bazureau JP. (2011). Leucettines, a Class of Potent Inhibitors of cdc2-Like Kinases and Dual Specificity, Tyrosine Phosphorylation Regulated Kinases Derived from the Marine Sponge Leucettamine B: Modulation of Alternative Pre-RNA Splicing. **J Med Chem** 54, 4172-4186.
112. Muller, S., Filippakopoulos, P., and Knapp, S. (2011). Bromodomains as therapeutic targets. **Expert Rev Mol Med**, 13:e29.
113. Hewings, DS., Wang, M., Philpott, M., Fedorov, O., Filippakopoulos, P., Picaud, S., Vuppusetty, C., Marsden, B., Knapp, S., Conway, S.J., Heightman, TD. (2011). **J. Med. Chem.** Oct 13;54(19):6761-6770.
114. Philpott, M., Yang, J., Tumber, T., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Keates, T., Felletar I., Ciulli, A., Knapp, S., Heightman, TD. (2011). Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. **Molecular BioSystems**, (10):2899-2908.
115. Ahmed, AA., Knapp, S., Sood, A.K., Bast. RC. (2012) Targeting therapies in cancer: opportunities in ovarian cancer. Chapter 12, RCOG. In press.
116. Fedorov O, Niesen FH, Knapp S. (2012). Kinase inhibitor selectivity profiling using differential scanning fluorimetry. **Methods Mol. Biol.**, 795:109-118.
117. Shrestha A, Hamilton G, O'Neill E, Knapp S, Elkins JM. (2012). Analysis of conditions affecting auto-phosphorylation of human kinases during expression in bacteria. **Protein Expr Purif.** 81(1):136-43.



118. Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S, Bracher F. (2012). Novel 1,2,3,4-tetrahydro-1-oxo- $\beta$ -carbolines as dual inhibitors of PIM and DAPK3 kinases. **J. Med. Chem.** 55(1):403-413.
119. Filippakopoulos P, Picaud S, Fedorov O, Keller M, Wrobel M, Morgenstern O, Bracher F, Knapp S. (2012) Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. **Bioorg Med Chem.**, 20(6):1878-86.
120. Adams CJ, Pike AC, Maniam S, Sharpe TD, Coutts AS, Knapp S, La Thangue NB, Bullock AN. (2012). The p53 cofactor Strap exhibits an unexpected TPR motif and oligonucleotide-binding (OB)-fold structure. **Proc Natl Acad Sci U S A**, 109(10),3778-3783.
121. Brennan, P., Filippakopoulos, P., Knapp, S. (2012). The Therapeutic Potential of Acetyl-lysine Competitive Inhibitors Targeting Bromodomains, **DTT**, **accepted**.
122. Hellwig, S., Miduturu, CV., Kanda, S., Zhang, J., Filippakopoulos, P., Salah, E., Deng, X., Choi, HG., Zhou, W., Hur, W, Knapp, S., Gray, NS., Smithgall, TE. (2012). Small-Molecule Inhibitors of the c-Fes Protein-Tyrosine Kinase. **Chemistry and Biology** 19(4):529-540.
123. Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J-P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Gingras, A-C., Pawson, T., Arrowsmith, C., Knapp, S. (2012). Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family. **Cell**, Mar 30;149(1):214-31.
124. Brault, L., Menter, T., Obermann, E.C., Knapp, S., Thommen, S., Schwaller, J., and Tzankov, A. (2012). PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. **Br J Cancer** 107, 491-500.
125. Chaikuad, A., Alfano, I., Kerr, G., Sanvitale, C.E., Boergermann, J.H., Triffitt, J.T., von Delft, F., Knapp, S., Knaus, P., and Bullock, A.N. (2012a). Structure of the BMP receptor ALK2 and implications for fibrodysplasia ossificans progressiva. **The Journal of Biological Chemistry** 287, 36990-36998.
126. De Antoni, A., Maffini, S., Knapp, S., Musacchio, A., and Santaguida, S. (2012). A small-molecule inhibitor of Haspin alters the kinetochore functions of Aurora B. **The Journal of Cell Biology** 199, 269-284.
127. Elkins, J.M., and Knapp, S. (2012). The structure of the full-length tetrameric PKA regulatory RII $\beta$  complex reveals the mechanism of allosteric PKA activation. **Sci Signal** 5, pe21.
128. Elkins, J.M., Santaguida, S., Musacchio, A., and Knapp, S. (2012). Crystal Structure of Human Aurora B in Complex with INCENP and VX-680. **Journal of Medicinal Chemistry** 55, 7841-7848.
129. Filippakopoulos, P., and Knapp, S. (2012). The bromodomain interaction module. **FEBS Lett** 586, 2692-2704.
130. Fish, P., Filippakopoulos, P., Bish, G., Brennan, P., Bunnage, M.E., Cook, A., Fedorov, O., Gerstenberger, B.S., Jones, H., Knapp, S., Marsden, B., Nocka, K., Owen, D.R., Picaud, S., Primiano, M., Ralph, M., Sciammetta, N., and Trzuppek, J. (2012). Identification of a chemical probe for BET bromodomain inhibition through optimization of a fragment-derived hit. **Journal of Medicinal Chemistry**. 55(22), 9831-9837.
131. Hewings, D.S., Rooney, T.P., Jennings, L.E., Hay, D.A., Schofield, C.J., Brennan, P.E., Knapp, S., and Conway, S.J. (2012). Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain-Acetyl-lysine Interactions. **Journal of medicinal chemistry**. In press.
132. Kettenbach, A.N., Wang, T., Faherty, B.K., Madden, D.R., Knapp, S., Bailey-Kellogg, C., and Gerber, S.A. (2012). Rapid determination of multiple linear kinase substrate motifs by mass spectrometry. **Chem Biol** 19, 608-618.

133. Matzuk, M.M., McKeown, M.R., Filippakopoulos, P., Li, Q., Ma, L., Agno, J.E., Lemieux, M.E., Picaud, S., Yu, R.N., Qi, J., Knapp, S., and Bradner, J.E. (2012). Small-Molecule Inhibition of BRDT for Male Contraception. **Cell** 150, 673-684
134. Meiby, E., Knapp, S., Elkins, J.M., and Ohlson, S. (2012). Fragment screening of cyclin G-associated kinase by weak affinity chromatography. **Anal Bioanal Chem.**
135. Pasquo, A., Consalvi, V., Knapp, S., Alfano, I., Ardini, M., Stefanini, S., and Chiaraluce, R. (2012). Structural stability of human protein tyrosine phosphatase rho catalytic domain: effect of point mutations. **PLoS One** 7, e32555.
136. Prudent, R., Vassal-Stermann, E., Nguyen, C.H., Pillet, C., Martinez, A., Prunier, C., Barette, C., Soleilhac, E., Filhol, O., Beghin, A., Valdameri, G., Honore, S., Aci-Seche, S., Grierson, D., Antonipillai, J., Li, R., Di Pietro, A., Dumontet, C., Braguer, D., Florent, J.C., Knapp, S., Bernard, O., and Lafanechere, L. (2012). Pharmacological Inhibition of LIM Kinase Stabilizes Microtubules and Inhibits Neoplastic Growth. **Cancer Res** 72, 4429-4439
137. Tahtouh, T., Elkins, J.M., Filippakopoulos, P., Soundararajan, M., Burgy, G., Durieu, E., Cochet, C., Schmid, R., Lo, D., Delhommel, F., Oberholzer, A., Laurence, P., Carreaux, F., Bazureau, J.P., Knapp, S., and Meijer, L. (2012). Selectivity, co-crystal structures and neuroprotective properties of Leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid Leucettamine B. **Journal of Medicinal Chemistry**. In press.
138. Vidler, L.R., Brown, N., Knapp, S., and Hoelder, S. (2012). Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites. *Journal of medicinal chemistry* 55, 7346-7359. **Journal of Medicinal Chemistry**. In press.
139. Zhang, W.S., Prakash, C., Sum, C., Gong, Y., Li, Y., Kwok, J.J., Thiessen, N., Pettersson, S., Jones, S.J., Knapp, S., Yang, H., and Chin, K.C. (2012). Bromodomain-Containing-Protein 4 (BRD4) Regulates RNA Polymerase II Serine 2 Phosphorylation in Human CD4+ T Cells. **The Journal of Biological Chemistry**. 287(51), 43137-43155.
140. Cheng, Z., Gong, Y., Ma, Y., Lu, K., Lu, X., Pierce, L.A., Thompson, R.C., Muller, S., Knapp, S., and Wang, J. (2013). Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma. **Clinical Cancer Research**. 19, 1748-1759.
141. Da Costa, D., Agathangelou, A., Perry, T., Weston, V., Petermann, E., Zlatanou, A., Oldreive, C., Wei, W., Stewart, G., Longman, J., Smith, E., Kearns, P., Knapp, S., and Stankovic, T. (2013). BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. **Blood Cancer J** 3, e126.
142. De Nicola, G.F., Martin, E.D., Chaikuad, A., Bassi, R., Clark, J., Martino, L., Verma, S., Sicard, P., Tata, R., Atkinson, R.A., Knapp, S., Conte, M.R., and Marber, M.S. (2013). Mechanism and consequence of the autoactivation of p38alpha mitogen-activated protein kinase promoted by TAB1. **Nat Struct Mol Biol** 20, 1182-1190.
143. Deng, X., Elkins, J.M., Zhang, J., Yang, Q., Erazo, T., Gomez, N., Choi, H.G., Wang, J., Dzamko, N., Lee, J.D., Sim, T., Kim, N., Alessi, D.R., Lizcano, J.M., Knapp, S., and Gray, N.S. (2013). Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. **Eur J Med Chem** 70, 758-767.
144. Ekambaram, R., Enkvist, E., Vaasa, A., Kasari, M., Raidaru, G., Knapp, S., and Uri, A. (2013). Selective Bisubstrate Inhibitors with Sub-nanomolar Affinity for Protein Kinase Pim-1. **ChemMedChem** 8, 909-913.

145. Elkins, J.M., Wang, J., Deng, X., Pattison, M.J., Arthur, J.S., Erazo, T., Gomez, N., Lizcano, J.M., Gray, N.S., and Knapp, S. (2013). X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor. **Journal of Medicinal Chemistry** 56, 4413-4421.
146. Ferguson, F.M., Fedorov, O., Chaikuad, A., Philpott, M., Muniz, J.R., Felletar, I., von Delft, F., Heightman, T., Knapp, S., Abell, C., and Ciulli, A. (2013). Targeting Low-Druggability Bromodomains: Fragment Based Screening and Inhibitor Design against the BAZ2B Bromodomain. **Journal of Medicinal Chemistry** 56, 10183-10187.
147. Fisher, K., Gee, F., Wang, S., Xue, F., Knapp, S., Philpott, M., Wells, C., Rodriguez, M., Snoek, L.B., Kammenga, J., and Poulin, G.B. (2013). Maintenance of muscle myosin levels in adult *C. elegans* requires both the double bromodomain protein BET-1 and sumoylation. **Biology open** 2, 1354-1363.
148. Gammons, M.V., Fedorov, O., Ivison, D., Du, C., Clark, T.L., Hopkins, C., Hagiwara, M., Dick, A.D., Cox, R.J., Harper, S.J., Hancox, J.C., Knapp, S., and Bates, D.O. (2013). Topical anti-angiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative-AMD. **Invest Ophthalmol Vis Sci.** 54(9):6052-62.
149. Harrington, L., Cheley, S., Alexander, L.T., Knapp, S., and Bayley, H. (2013). Stochastic detection of Pim protein kinases reveals electrostatically enhanced association of a peptide substrate. **PNAS** 110, E4417-4426.
150. Hay, D., Fedorov, O., Filippakopoulos, P., Martin, S., Philpott, M., Picaud, S., Hewings, D.S., Uttakar, S., Heightman, T.D., Conway, S.J., Knapp, S., and Brennan, P.E. (2013). The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains. **MedChemComm** 4, 140-144.
151. Hewings, D.S., Fedorov, O., Filippakopoulos, P., Martin, S., Picaud, S., Tumber, A., Wells, C., Olcina, M.M., Freeman, K., Gill, A., Ritchie, A.J., Sheppard, D.W., Russell, A.J., Hammond, E.M., Knapp, S., Brennan, P.E., and Conway, S.J. (2013). Optimization of 3,5-dimethylisoxazole derivatives as potent BET bromodomain ligands. **Journal of Medicinal Chemistry.** 56(8):3217-27.
152. Knapp, S. (2013). Testis specific gene expression drives disease progression and Rituximab resistance in lymphoma. **EMBO Mol Med** 5, 1149-1150.
153. Knapp, S., Arruda, P., Blagg, J., Burley, S., Drewry, D.H., Edwards, A., Fabbro, D., Gillespie, P., Gray, N.S., Kuster, B., Lackey, K.E., Mazzafera, P., Tomkinson, N.C., Willson, T.M., Workman, P., and Zuercher, W.J. (2013). A public-private partnership to unlock the untargeted kinome. **Nature Chem. Bio.** 9, 3-6.
154. Knapp, S., and Weinmann, H. (2013). Small-Molecule Modulators for Epigenetics Targets. **ChemMedChem.** (11):1885-91.
155. Lori, C., Lantella, A., Pasquo, A., Alexander, L.T., Knapp, S., Chiaraluce, R., and Consalvi, V. (2013). Effect of single amino acid substitution observed in cancer on pim-1 kinase thermodynamic stability and structure. **PLoS one** 8, e64824.
156. Lu, M., Breysens, H., Salter, V., Zhong, S., Hu, Y., Baer, C., Ratnayaka, I., Sullivan, A., Brown, N.R., Endicott, J., Knapp, S., Kessler, B.M., Middleton, M.R., Siebold, C., Jones, E.Y., Sviderskaya, E.V., Cebon, J., John, T., Caballero, O.L., Goding, C.R., and Lu, X. (2013). Restoring p53 Function in Human

Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP. **Cancer Cell** 23(5), 618-633.

157. Mehellou, Y., Alessi, D.R., Macartney, T.J., Szklarz, M., Knapp, S., and Elkins, J.M. (2013). Structural insights into the activation of MST3 by MO25. **Biochem Biophys Res Commun** 431, 604-609.
158. Myrianthopoulos, V., Kritsanida, M., Gaboriaud-Kolar, N., Magiatis, P., Ferandin, Y., Durieu, E., Lozach, O., Cappel, D., Soundararajan, M., Filippakopoulos, P., Sherman, W., Knapp, S., Meijer, L., Mikros, E., and Skaltsounis, A.L. (2013). Novel Inverse Binding Mode of Iridium Derivatives Yields Improved Selectivity for DYRK Kinases. **ACS Med Chem Lett** 4, 22-26.
159. Newman, R.H., Hu, J., Rho, H.S., Xie, Z., Woodard, C., Neiswinger, J., Cooper, C., Shirley, M., Clark, H.M., Hu, S., Hwang, W., Seop Jeong, J., Wu, G., Lin, J., Gao, X., Ni, Q., Goel, R., Xia, S., Ji, H., Dalby, K.N., Birnbaum, M.J., Cole, P.A., Knapp, S., Ryazanov, A.G., Zack, D.J., Blackshaw, S., Pawson, T., Gingras, A.C., Desiderio, S., Pandey, A., Turk, B.E., Zhang, J., Zhu, H., and Qian, J. (2013). Construction of human activity-based phosphorylation networks. **Mol Syst Biol** 9, 655.
160. Picaud, S., Da Costa, D., Thanasopoulou, A., Filippakopoulos, P., Fish, P.V., Philpott, M., Fedorov, O., Brennan, P., Bunnage, M.E., Owen, D.R., Bradner, J.E., Tanieri, P., O'Sullivan, B., Muller, S., Schwaller, J., Stankovic, T., and Knapp, S. (2013a). PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains. **Cancer Research** 73, 3336-3346.
161. Picaud, S., Wells, C., Felletar, I., Brotherton, D., Martin, S., Savitsky, P., Diez-Dacal, B., Philpott, M., Bountra, C., Lingard, H., Fedorov, O., Muller, S., Brennan, P.E., Knapp, S., and Filippakopoulos, P. (2013b). RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. **PNAS** 110, 19754-19759.
162. Schafer, G., Milic, J., Eldahshan, A., Gotz, F., Zuhlke, K., Schillinger, C., Kreuchwig, A., Elkins, J.M., Abdul Azeez, K.R., Oder, A., Moutty, M.C., Masada, N., Beerbaum, M., Schlegel, B., Niquet, S., Schmieder, P., Krause, G., von Kries, J.P., Cooper, D.M., Knapp, S., Rademann, J., Rosenthal, W., and Klusmann, E. (2013). Highly Functionalized Terpyridines as Competitive Inhibitors of AKAP-PKA Interactions. **Angewandte Chemie**. 52(46):12187-91
163. Soundararajan, M., Roos, A.K., Savitsky, P., Filippakopoulos, P., Kettenbach, A.N., Olsen, J.V., Gerber, S.A., Eswaran, J., Knapp, S., and Elkins, J.M. (2013). Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate Recognition. **Structure** 21, 986-996.
164. van Ameijde, J., Overvoorde, J., Knapp, S., den Hertog, J., Ruijtenbeek, R., and Liskamp, R.M. (2013). A versatile spectrophotometric protein tyrosine phosphatase assay based on 3-nitrophosphotyrosine containing substrates. **Analytical Biochemistry** 448C, 9-13.
165. Vidler, L.R., Filippakopoulos, P., Fedorov, O., Picaud, S., Martin, S., Tomsett, M., Woodward, H., Brown, N., Knapp, S., and Hoelder, S. (2013). Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening. **Journal of Medicinal Chemistry** 56, 8073-8088.
166. Yu, W., Smil, D., Li, F., Tempel, W., Fedorov, O., Nguyen, K.T., Bolshan, Y., Al-Awar, R., Knapp, S., Arrowsmith, C.H., Vedadi, M., Brown, P.J., and Schapira, M. (2013). Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. **Bioorganic & Medicinal Chemistry** 21, 1787-1794.
167. Canning, P., Cooper, C.D., Krojer, T., Murray, J.W., Pike, A.C., Chaikuad, A., Keates, T., Thangaratnarajah, C., Hojzan, V., Ayinampudi, V., Marsden, B.D., Gileadi, O., Knapp, S., von Delft, F.,

- and Bullock, A.N. (2013). Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. **J Biol Chem** 288, 28304.
168. Abdul Azeez, K.R., Knapp, S., Fernandes, J.M., Klussmann, E., and Elkins, J.M. (2014). The Crystal Structure of the RhoA : AKAP-Lbc DH-PH Domain Complex. **The Biochemical Journal**. 464(2):231-9
169. Brady, D.C., Crowe, M.S., Turski, M.L., Hobbs, G.A., Yao, X., Chaikuad, A., Knapp, S., Xiao, K., Campbell, S.L., Thiele, D.J., and Counter, C.M. (2014). Copper is required for oncogenic BRAF signalling and tumorigenesis. **Nature** 509, 492-496.
170. Chaikuad, A., E, M.C.T., Zimmer, J., Liang, Y., Gray, N.S., Tarsounas, M., and Knapp, S. (2014a). A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. **Nature Chem. Biol.** 10, 853-860.
171. Chaikuad, A., Keates, T., Vincke, C., Kaufholz, M., Zenn, M., Zimmermann, B., Gutierrez, C., Zhang, R.G., Hatzos-Skintges, C., Joachimiak, A., Muyldermans, S., Herberg, F.W., Knapp, S., and Muller, S. (2014b). Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies. **The Biochemical Journal** 459, 59-69.
172. Chaikuada, A., Petros, A., Fedorov, O., Xu, J., and Knapp, S. (2014). Structure-based approaches towards identification of fragments for the low-druggability ATAD2 bromodomain. **MedChemComm**. in press
173. Chen, C., Ha, B.H., Thevenin, A.F., Lou, H.J., Zhang, R., Yip, K.Y., Peterson, J.R., Gerstein, M., Kim, P.M., Filippakopoulos, P., Knapp, S., Boggon, T.J., and Turk, B.E. (2014). Identification of a major determinant for serine-threonine kinase phosphoacceptor specificity. **Molecular Cell** 53, 140-147.
174. Ciceri, P., Muller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J.P., Lasater, E.A., Pallares, G., Picaud, S., Wells, C., Martin, S., Wodicka, L.M., Shah, N.P., Treiber, D.K., and Knapp, S. (2014). Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. **Nature Chem. Bio.** 10, 305-312.
175. Cowan-Jacob, S.W., Jahnke, W., and Knapp, S. (2014). Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. **Future Medicinal Chemistry** 6, 541-561.
176. Ekambaram, R., Enkvist, E., Manoharan, G.B., Ugandi, M., Kasari, M., Viht, K., Knapp, S., Issinger, O.G., and Uri, A. (2014). Benzoselenadiazole-based responsive long-lifetime photoluminescent probes for protein kinases. **Chemical Communications** 50, 4096-4098.
177. Fedorov, O., Lingard, H., Wells, C., Monteiro, O.P., Picaud, S., Keates, T., Yapp, C., Philpott, M., Martin, S.J., Felletar, I., Marsden, B.D., Filippakopoulos, P., Muller, S., Knapp, S., and Brennan, P.E. (2014). [1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains. **Journal of Medicinal Chemistry** 57, 462-476.
178. Filippakopoulos, P., and Knapp, S. (2014). Targeting bromodomains: epigenetic readers of lysine acetylation. **Nature Reviews Drug Discovery** 13, 337-356.
179. Guetzoyan, L., Ingham, R.J., Nikbin, N., Rossignol, J., Wolling, M., Baumert, M., Burgess-Brown, N.A., Strain-Damerell, C.M., Shrestha, L., Brennan, P.E., Fedorov, O., Knapp, S., and Ley, S.V. (2014). Machine-assisted synthesis of modulators of the histone reader BRD9 using flow methods of chemistry and frontal affinity chromatography. **MedChemComm** 5, 540-546.

180. Hay, D.A., Fedorov, O., Martin, S., Singleton, D.C., Tallant, C., Wells, C., Picaud, S., Philpott, M., Monteiro, O.P., Rogers, C.M., Conway, S.J., Rooney, T.P., Tumber, A., Yapp, C., Filippakopoulos, P., Bunnage, M.E., Muller, S., Knapp, S., Schofield, C.J., and Brennan, P.E. (2014). Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. **JACS** 136, 9308-9319.
181. Homan, K.T., Larimore, K.M., Elkins, J.M., Szklarz, M., Knapp, S., and Tesmer, J.J. (2014). Identification and Structure-Function Analysis of Subfamily Selective G Protein-Coupled Receptor Kinase Inhibitors. **ACS Chemical Biology**. in press
182. Horne, G.A., Stewart, H.J., Dickson, J., Knapp, S., Ramsahoye, B., and Chevassut, T. (2014). Nanog Requires BRD4 to Maintain Murine Embryonic Stem Cell Pluripotency and Is Suppressed by Bromodomain Inhibitor JQ1 Together with Lefty1. **Stem Cells and Development**. in press.
183. Huber, K.V., Salah, E., Radic, B., Gridling, M., Elkins, J.M., Stukalov, A., Jemth, A.S., Gokturk, C., Sanjiv, K., Stromberg, K., Pham, T., Berglund, U.W., Colinge, J., Bennett, K.L., Loizou, J.I., Helleday, T., Knapp, S., and Superti-Furga, G. (2014). Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. **Nature** 508, 222-227.
184. Knapp, S., and Sundstrom, M. (2014). Recently targeted kinases and their inhibitors-the path to clinical trials. **Current Opinion in Pharmacology** 17C, 58-63.
185. Liu, S., Knapp, S., and Ahmed, A.A. (2014). The Structural Basis of PI3K Cancer Mutations: From Mechanism to Therapy. **Cancer Research** 74, 641-646.
186. Maiolica, A., de Medina-Redondo, M., Schoof, E.M., Chaikuad, A., Villa, F., Gatti, M., Jeganathan, S., Lou, H.J., Novy, K., Hauri, S., Toprak, U.H., Herzog, F., Meraldi, P., Penengo, L., Turk, B.E., Knapp, S., Linding, R., and Aebersold, R. (2014). Modulation of the chromatin phosphoproteome by the Haspin protein kinase. **Molecular & Cellular Proteomics** : MCP 13, 1724-1740.
187. Muller, S., and Knapp, S. (2014). Discovery of BET bromodomain inhibitors and their role in target validation. **MedChemComm** 5, 288-296.
188. Nagarajan, S., Hossan, T., Alawi, M., Najafova, Z., Indenbirken, D., Bedi, U., Taipaleenmaki, H., Ben-Batalla, I., Scheller, M., Loges, S., Knapp, S., Hesse, E., Chiang, C.M., Grundhoff, A., and Johnsen, S.A. (2014). Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription. **Cell Reports** 8, 460-469.
189. Philpott, M., Rogers, C.M., Yapp, C., Wells, C., Lambert, J.P., Strain-Damerell, C., Burgess-Brown, N.A., Gingras, A.C., Knapp, S., and Muller, S. (2014). Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching. **Epigenetics & Chromatin** 7, 14.
190. Rooney, T.P., Filippakopoulos, P., Fedorov, O., Picaud, S., Cortopassi, W.A., Hay, D.A., Martin, S., Tumber, A., Rogers, C.M., Philpott, M., Wang, M., Thompson, A.L., Heightman, T.D., Pryde, D.C.,
191. Cook, A., Paton, R.S., Muller, S., Knapp, S., Brennan, P.E., and Conway, S.J. (2014). A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation-pi interaction. **Angewandte Chemie** 53, 6126-6130.
192. Rudolf, A.F., Skovgaard, T., Knapp, S., Jensen, L.J., and Berthelsen, J. (2014). A comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determination. **PLoS one** 9, e98800.

193. Selner, N.G., Luechapanichkul, R., Chen, X., Neel, B.G., Zhang, Z.Y., Knapp, S., Bell, C.E., and Pei, D. (2014). Diverse levels of sequence selectivity and catalytic efficiency of protein-tyrosine phosphatases. **Biochemistry** 53, 397-412.
194. Wang, J., Knapp, S., Pyne, N.J., Pyne, S., and Elkins, J.M. (2014). Crystal Structure of Sphingosine Kinase 1 with PF-543. **ACS Medicinal Chemistry Letters** 5, 1329-1333.
195. Wilbek, T.S., Skovgaard, T., Sorrell, F.J., Knapp, S., Berthelsen, J., and Stromgaard, K. (2014). Identification and Characterization of a Small-Molecule Inhibitor of Death-Associated Protein Kinase 1. **Chembiochem** . in press
196. Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., and Gray, N.S. (2014). Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? **ACS Chemical Biology**. 9(6):1230-41.

## Patents:

1. Trosset, J-Y., Dalvit, C., Knapp, S., Moll, J., Sergio, M., Sundstrom M. (2003) Interaction inhibitors of Tcf-4 with beta-catenin. WO03006447, WO 2003006447 A2 20030123
2. Valsasina, B., Cristiani, C., Knapp, S., Thieffine, S., Perego, R., Saccardo, M-B. Kalisz, H.M. (2003). Truncated human dbf4 in complex with its interacting partners (catalytic subunits) such as human cdc7, and methods for the production of monodisperse heterodimers for identification and optimization of inhibitors thereof. WO/2004/099243.